Inventor · disambiguated record
Alfica Sehgal
Also filed as: SEHGAL ALFICA
20 granted patents·31 pending applications·140 citations·filing 2011–2025
94Inventor score
Files withALNYLAM PHARMACEUTICALS INC28CAMP4 THERAPEUTICS CORP15GENZYME CORP3ALNYLAM PHARMACEUTICALS1BETTENCOURT BRIAN1
Top patents by PatentIndex Score
51 records- 0196US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 0296US9879261B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·10 cites·7 claims
- 0396US9127274B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS·Filed 2013·Granted Sep 8, 2015·51 cites·62 claims
- 0494US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 0593US9574192B2Serapina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 21, 2017·14 cites·36 claims
- 0691US9376680B2Serpinc1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jun 28, 2016·7 cites·55 claims
- 0791US9228188B2Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionBETTENCOURT BRIAN·Filed 2012·Granted Jan 5, 2016·8 cites·22 claims
- 0890US10935917B2Serpina1 siRNAs: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·2 cites·29 claims
- 0990US10030244B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 24, 2018·6 cites·28 claims
- 1088US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 1185US10683504B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·2 cites·19 claims
- 1285US2023365965A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2023·Application pending·0 cites
- 1384US11542290B2Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2019·Granted Jan 3, 2023·2 cites·6 claims
- 1484US10920223B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Feb 16, 2021·2 cites·45 claims
- 1583US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1683US2024255880A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1779US9944671B2Compositions and methods directed to treating liver fibrosisHINKLE GREG·Filed 2011·Granted Apr 17, 2018·6 cites·8 claims
- 1879US2022155716A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1979US2025034193A1Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2024·Application pending·0 cites
- 2078US10077444B2Compositions and methods for inhibiting expression of the LECT2 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Sep 18, 2018·2 cites·71 claims
- 2177US12071619B2SERPINA1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 27, 2024·0 cites·18 claims
- 2276US12145963B2Phenothiazine derivatives and uses thereofCAMP4 THERAPEUTICS CORP·Filed 2022·Granted Nov 19, 2024·0 cites·1 claims
- 2376US2021041823A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2476US2023256001A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2576US2021254063A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2020·Application pending·0 cites
- 2675US12319916B2Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAsCAMP4 THERAPEUTICS CORP·Filed 2024·Granted Jun 3, 2025·0 cites·15 claims
- 2775US11266655B2Methods and compositions for treating urea cycle disordersCAMP4 THERAPEUTICS CORP·Filed 2020·Granted Mar 8, 2022·1 cites·10 claims
- 2872US2022213473A1Compositions and methods for inhibiting expression of the lect2 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2972US2020216844A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFGENZYME CORP·Filed 2018·Application pending·0 cites
- 3071US2022307083A1Assays and methods for determining activity of a therapeutic agent in a subjectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3169US2018120749A1Serpina1 sirnas: compositions of matter and methods of treatmentALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3269US2025205272A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 3366US10669303B2Compositions and methods directed to treating liver fibrosisALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·0 cites·13 claims
- 3466US2019292595A1Assays and methods for determining activity of a therapeutic agent in a subjectALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3563US2021087218A1Compositions and methods directed to treating liver fibrosisALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3663US2025243488A1Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnasCAMP4 THERAPEUTICS CORP·Filed 2024·Application pending·0 cites
- 3759US2016257954A1SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3859US2014235693A1Serpina1 sirnas: compositions of matter and methods of treatmentSEHGAL ALFICA·Filed 2012·Application pending·0 cites
- 3957US2019119674A1Compositions and methods for inhibiting expression of the lect2 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4057US2025290072A1Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnasCAMP4 THERAPEUTICS CORP·Filed 2025·Application pending·0 cites
- 4156US2014275211A1Assays and methods for determining activity of a therapeutic agent in a subjectSAH DINAH·Filed 2012·Application pending·0 cites
- 4255US2022168316A1Methods and compositions for treating urea cycle disordersCAMP4 THERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 4355US2025250575A1Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnasCAMP4 THERAPEUTICS CORP·Filed 2025·Application pending·0 cites
- 4454US2024360451A1Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnasCAMP4 THERAPEUTICS CORP·Filed 2022·Application pending·0 cites
- 4550US2016186172A1Compositions and methods for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expressionALNYLAM PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4648US2020339987A1Assays and methods for determining expression of the lect2 geneALNYLAM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4746US2021161997A1Treating diseases via targeted modulation of gene signaling networksCAMP4 THERAPEUTICS CORP·Filed 2019·Application pending·0 cites
- 4845US2025320496A1Modulation of abcb11 gene transcription using antisense oligonucleotides targeting regulatory rnasCAMP4 THERAPEUTICS CORP·Filed 2025·Application pending·0 cites
- 4938US2020316038A1Methods and compositions for treating urea cycle disorders, in particular otc deficiencyCAMP4 THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
- 5038US2020208128A1Methods of treating liver diseasesCAMP4 THERAPEUTICS CORP·Filed 2018·Application pending·0 cites
Showing the top 50 of 51 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Alfica Sehgal files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →